Last reviewed · How we verify
Non-adherent to 5ARI therapy
At a glance
| Generic name | Non-adherent to 5ARI therapy |
|---|---|
| Also known as | Proscar® is a registered trademark of Merck, Avodart® is a registered trademark of GlaxoSmithKline |
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Demonstrating the Clinical and Economic Benefit of 5 Alpha Reductase Inhibitor Adherence in Benign Prostatic Hyperplasia
- Benefits of Adherence to 5-alpha Reductase Inhibitor Treatment in Men With Enlarged Prostate: An Assessment of Medicare and Medicaid Patients Using the MarketScan Database
- Establishing the Benefits of Adherence to Enlarged Prostate Treatment: A Validation Study Linking Adherence to Outcomes Using the Market Scan Database
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Non-adherent to 5ARI therapy CI brief — competitive landscape report
- Non-adherent to 5ARI therapy updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI